MedTrace Logo

Imaging and Predictive Modelling of Proliferative Vitreoretinopathy.

NCT07682025 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-07-02

No results posted yet for this study

Summary

Patients with retinal detachment are at risk of recurrence and failure of surgery requiring multiple surgeries due to a condition called proliferative vitreoretinopathy (PVR).

Study aims to help tailor patients' treatments and improve outcomes by:

\[i\] studying imaging biomarkers of PVR, and \[ii\] develop AI models for PVR detection.

Inclusion:

* Patients with 'complicated' retinal detachment with PVR recruited to a phase 1 dose-finding trial called MORPH-1.
* Patients with 'simple' retinal detachment without PVR recruited to a PhD study.

Non -invasive multimodal imaging and anonymized imaging will be used to study imaging biomarkers of PVR and develop deep learning models to predict PVR in collaboration with an artificial intelligence (AI) expert team at UCL Institute of Ophthalmology.

Conditions

  • Proliferative Vitreoretinopathy

Sponsors & Collaborators

  • University College, London

    lead OTHER

Principal Investigators

  • James Bainbridge · University College, London

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-12
Primary Completion
2027-10-15
Completion
2027-10-15

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07682025 on ClinicalTrials.gov